Kenzar Plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kenzar Plus

Quick Facts

Property Description
Active ingredients Losartan (Losartan Potassium), Hydrochlorothiazide (HCTZ)
Form Film-Coated Tablet
Pharmacological class Angiotensin II Receptor Blocker & Thiazide Diuretic Combination
Common use Management of High Blood Pressure (Hypertension)
Origin / Status Synthetic / Prescription Drug (Rx)

What Type of Medicine is Kenzar Plus?

Kenzar Plus is a synthetic fixed-dose combination medication that is administered via the oral route as a Film-Coated Tablet. It is officially classified within the high-level pharmacological class of Angiotensin II Inhibitors with Thiazides, a category of agents used for controlling blood pressure. This product is manufactured by The ACME Laboratories, confirming its status as a Prescription Drug (Rx).

The combination is designed to deliver two distinct active ingredientsLosartan and Hydrochlorothiazide—to achieve a synergistic therapeutic effect. Losartan operates as an Angiotensin II Receptor Blocker (ARB), promoting vessel relaxation, while Hydrochlorothiazide functions as a thiazide diuretic to address fluid volume.

Composition and General Therapeutic Purpose

The core composition consists of Losartan (Losartan Potassium) and Hydrochlorothiazide (HCTZ). Supported by pharmacological studies, this combination is typically used for patients who require a robust, dual-pathway strategy for blood pressure reduction when monotherapy with a single agent is insufficient.

This dual action is highly effective because it simultaneously addresses both key mechanical factors in blood pressure elevation: reducing vascular constriction and decreasing fluid volume. The general purpose of the medication is therefore the effective management of systemic Hypertension, which helps to mitigate long-term cardiovascular risks, including the reduction of strain on the heart and the potential for adverse outcomes in high-risk patients.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Kenzar Plus?

Possible side effects and safety information

Kenzar Plus (Losartan/Hydrochlorothiazide) is associated with adverse reactions that are officially classified by frequency and System-Organ Class (SOC) according to government regulatory documents.

Common adverse reactions documented in clinical trials include dizziness, upper respiratory infection (such as the common cold), nasal congestion, and back pain. Other documented effects are classified as Uncommon, Rare, or Post-Marketing experience with Frequency Not Known, affecting systems such as the nervous system, gastrointestinal tract, skin, and metabolism.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights several serious adverse reactions and risks. A major constraint is the Black Box Warning for Fetal Toxicity, as use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. Other serious effects include Angioedema (swelling of the face, lips, tongue, and/or throat), symptomatic hypotension, and renal function deterioration, including acute renal failure. Additionally, the diuretic component carries a documented risk of Acute Myopia and Secondary Angle-Closure Glaucoma, typically occurring early in treatment.

Population-Specific Safety Notes

The combination is contraindicated in patients with Anuria (absence of urine formation), severe hepatic impairment, and severe renal impairment (creatinine clearance le 30 mL/min). Patients with volume or salt depletion may experience symptomatic low blood pressure, especially upon the initiation of treatment. Contraindication also applies to co-administration with Aliskiren in patients with diabetes or moderate-to-severe renal impairment. These constraints establish the formal regulatory boundaries for its use.

Overdose and Emergency Response

Kenzar Plus Overdose and when to seek help

The official regulatory profile for Kenzar Plus overdose is defined by the severe physiological effects resulting from its two active components.

Overdose Scope Official Regulatory Statement
Documented Overdose Presentations Overdose is documented to present as hypotension (extremely low blood pressure), tachycardia (rapid heart rate), or potentially bradycardia (slow heart rate). Excessive diuresis may lead to dehydration, somnolence, and critical electrolyte imbalances (e.g., low sodium or potassium).
Physiological Systems Affected Cardiovascular/Circulatory System, Renal Function, and Electrolyte/Fluid Balance.
Population-specific overdose notes Neonates with a history of in utero exposure must be observed for hypotension and hyperkalemia, with supportive measures such as dialysis or exchange transfusions potentially required.
Emergency-response statements Immediate medical attention must be sought. Regulators require contacting a Poison Help line or emergency services at once if an overdose is suspected, especially if the person has collapsed or cannot be awakened.

Resulting Overdose Structure

The profile is classified by the risk of Profound Hypotension and Severe Electrolyte Imbalance, which can escalate to acute renal failure. No specific antidote is known for this combination medicine. Management is defined as symptomatic and supportive treatment, focusing on measures like establishing intravascular volume and considering gastrointestinal decontamination for recent ingestion. The Losartan component is not considered removable by haemodialysis.

Therapeutic Uses of Kenzar Plus

What Kenzar Plus Treats: Main Uses and Benefits

Kenzar Plus (Losartan/Hydrochlorothiazide) is commonly used to help with high blood pressure and may assist with reducing the probability of cardiovascular events in specific high-risk patients. The tablets are used for treatment of hypertension and the reduction of the risk of stroke in patients with hypertension and Left Ventricular Hypertrophy.

This medication is generally applied in clinical settings where systemic imbalance requires a robust, dual-agent strategy because monotherapy is insufficient. It is commonly used to help with symptoms related to systemic imbalance, such as fluid retention and peripheral edema (swelling), in addition to the primary goal of lowering elevated blood pressure readings.

“The combination approach may assist the patient during episodes by easing distress and helps with maintaining functional stability by managing fluid overload.”

The therapeutic domain focuses on managing cardiovascular risk by easing the impact of sustained high pressure in conditions involving organ-specific functional stress. This supports general well-being during symptomatic phases and contributes to easing the overall symptom load.

Quick Fact: Relief for Fluid-Related Symptoms
Kenzar Plus is commonly used to help with fluid retention and swelling (edema) in hypertensive patients, a benefit derived from its diuretic component.

Regulatory References

  1. LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE tablet, film coated - DailyMed

Eligibility and Restrictions for Use

Kenzar Plus (Losartan/Hydrochlorothiazide) is officially designated for use in adults with hypertension, including older adults for whom initial dosage adjustments are not typically required. However, government regulatory documents establish specific populations who must not use the medicine, as well as groups for whom use is restricted.

Contraindicated Populations (Must Not Use)

  • Pregnancy: The medication is strictly contraindicated during the second and third trimesters due to the risk of fetal injury and must be discontinued immediately upon detection of pregnancy.
  • Allergy: Contraindicated in patients with known hypersensitivity to Losartan, Hydrochlorothiazide, or any sulfonamide-derived drug.
  • Organ Function: Patients with anuria (inability to form or pass urine) or severe renal impairment (creatinine clearance le 30 mL/min) are prohibited from use.
  • Comorbidity/Interaction: Contraindicated for coadministration with aliskiren in patients with diabetes mellitus.

Restricted or Not Recommended Use

Use is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established in this age group. The medicine is also not recommended for patients with severe hepatic impairment. For patients who are breastfeeding, a clinical decision to discontinue either nursing or the medicine must be made, as the components may pass into milk.

What should I know about interactions with other medicines?

The official interaction profile for Kenzar Plus (Losartan/Hydrochlorothiazide) is defined by strict regulatory constraints regarding specific combinations. Co-administration with Aliskiren is formally contraindicated in patients with Diabetes Mellitus or severe renal impairment, restricting dual blockade of the Renin-Angiotensin System (RAS). The drug is also contraindicated in conditions such as Severe Hepatic Impairment and Severe Renal Impairment (Creatinine Clearance le 30 mL/min), as these conditions significantly alter Losartan's plasma concentrations. Interactions with Lithium pose a risk of toxicity due to reduced renal clearance. NSAIDs are documented to increase the risk of renal impairment and reduce the efficacy of the antihypertensive effect.

Substances that increase serum potassium, such as potassium-sparing diuretics or supplements, heighten the risk of hyperkalemia. Pharmacokinetic interactions occur with enzyme modulators like Fluconazole and Rifampicin, which alter Losartan and its active metabolite exposure via CYP2C9 and CYP3A4 pathways. Furthermore, absorption of Hydrochlorothiazide is reduced by resins such as Cholestyramine and Colestipol, requiring mandatory dose separation of at least 4 hours before or 4 to 6 hours after the resin. These documented statements establish the prohibitions and restrictions based solely on the official data describing combined effects on drug exposure, physiological parameters, or clearance.

Mechanism of Action

️ AT₁ Receptor Blockade and Vascular Tone Modulation (Losartan)

The Losartan component acts within the domain of humoral signaling by selectively blocking the Angiotensin II Type 1 (≈AT₁) receptor. This molecular antagonism prevents the binding of Angiotensin II from initiating its signal cascade in vascular smooth muscle cells. The primary physiological consequence is arterial relaxation (vasodilation), which reduces Systemic Vascular Resistance (SVR).


NaCl Symporter Inhibition and Circulating Volume Adjustment (Hydrochlorothiazide)

The Hydrochlorothiazide (HCTZ) component engages the domain of renal electrolyte transport. It achieves this by directly inhibiting the Sodium Chloride (NaCl) co-transporter located in the kidney's distal convoluted tubules. This inhibition blocks the reabsorption of salt and, by osmotic action, water. This action facilitates diuresis, resulting in a reduction in circulating fluid volume.


Dual-Pathway Synergy and System Control

Kenzar Plus utilizes a dual-pathway mechanism where Losartan manages vascular tension and HCTZ manages fluid volume. Losartan intercepts the compensatory RAAS activation that can be triggered by HCTZ-induced volume loss. The coordinated reduction of vascular resistance and fluid volume results in a pronounced physiological effect on arterial pressure.

Dosage and Administration Information

How to Use Kenzar Plus

Kenzar Plus (Losartan/Hydrochlorothiazide) is an oral fixed-dose combination tablet used for chronic management, not typically as the initial medicine for high blood pressure. Its administration follows a strict protocol for dosage, frequency, and patient-specific conditions as outlined in prescribing information.


Official Administration Protocol

Usage Parameter Guideline
Route of Administration Oral via film-coated tablet only.
Standard Adult Starting Dose The usual starting dose is 50 mg/12.5 mg once daily.
Maximum Labeled Dose The dose should not exceed 100 mg/25 mg once daily.
Dosing Frequency The medicine is taken once daily.
Timing Relative to Food The tablet may be administered with or without food.
Dose Titration Dosage may be increased after a minimum of approximately three weeks of therapy if blood pressure remains uncontrolled.

Administration Constraints and Special Populations

This medication is taken as a whole tablet and should not be crushed or chewed. In general, the fixed-dose combination is not recommended for use in children and adolescents under the age of 18 due to insufficient experience in this population. The use of this combination is restricted in patients with severe renal impairment (creatinine clearance < 30 mL/min) or severe hepatic impairment. If a dose is missed, instructions advise taking it as soon as remembered; however, if it is near the time of the next scheduled dose, the missed dose should be skipped, and the patient should resume the regular schedule. A double dose should not be taken to compensate.

Recent Clinical Evidence

Kenzar Plus: Recent Clinical Evidence

Evidence for Use in General High Blood Pressure Management

Research into the Losartan/Hydrochlorothiazide combination primarily involves multiple Randomized Controlled Trials (RCTs) conducted over short-term periods, typically lasting 4 to 12 weeks. These studies were used to explore the regimen's effect on blood pressure measured in the arm, specifically recording changes in sitting systolic and diastolic blood pressure. Trials included adult patients with essential hypertension whose blood pressure levels were not sufficiently addressed by a single medication alone. Studies monitored changes in blood pressure, including comparisons against both a placebo and Losartan monotherapy. Findings described patterns in how blood pressure values evolved over the observed time intervals. Existing studies, however, provide limited insight into the long-term association with major cardiovascular events for the general hypertensive population.

Evidence for Major Cardiovascular Risk Reduction

Research exploring the regimen's association with long-term clinical events, such as stroke, stems primarily from one large-scale, long-term Randomized Controlled Trial (RCT). This research was focused on a specific, high-risk group: adults (aged 55–80) with high blood pressure and evidence of Left Ventricular Hypertrophy (LVH). The study monitored participants over approximately 4.8 years, tracking major cardiovascular events. Research outcomes included tracking events such as stroke, myocardial infarction (heart attack), and overall cardiovascular mortality. The findings described patterns in the rates of these major events when comparing the Losartan-based regimen to another active blood pressure medication.

What is Still Uncertain About Kenzar Plus

Research evidence highlights several areas where data remain insufficient or inconsistent: the research is limited regarding patients without Left Ventricular Hypertrophy (LVH) and the patterns observed in the key long-term trial. Specific findings regarding major clinical events were reported to be inconsistent among Black patient populations, suggesting that the overall observed pattern in the pivotal trial may not apply to everyone equally. Furthermore, long-term effects of the combination extending past five years, particularly on metabolic health, are not fully established. Data for the use in children under the age of six and for women who are pregnant or nursing are also limited or excluded from clinical trials in certain jurisdictions.

Key Studies & References

  1. LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE tablet, film coated - DailyMed (NIH National Library of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Kenzar Plus (FAQ)


Q: What is the difference between Kenzar Plus and Kenzar alone?

A: Kenzar Plus is a fixed-dose combination that contains two active ingredients: Losartan (an ARB) and Hydrochlorothiazide (a diuretic). Kenzar alone is Losartan monotherapy and contains only the Losartan component. The combination product is generally used when the management of high blood pressure requires two different types of medication.


Q: How quickly does Kenzar Plus start working after the first dose?

A: While some blood pressure reduction may start sooner, the maximum antihypertensive effect of the Losartan component is typically achieved after approximately three to six weeks of continuous therapy. Official information indicates that the active drug metabolite has a half-life of 6 to 9 hours.


Q: Is Kenzar Plus a 'water pill' (diuretic)?

A: Yes, the combination contains Hydrochlorothiazide, which is a type of diuretic often referred to as a 'water pill.' This component works in the kidney to inhibit the reabsorption of salt and water, thereby helping to reduce the body's fluid volume.


Q: Are there any common over-the-counter (OTC) pain relievers that interact with Kenzar Plus?

A: Regulatory documents describe an interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include certain common over-the-counter pain relievers. Regulatory warnings indicate that co-administration may increase the risk of kidney function issues and could reduce the antihypertensive effect of this medication.


Q: Can Kenzar Plus cause fatigue or dizziness?

A: Dizziness is listed as a common adverse reaction observed in clinical trials. Fatigue has also been reported as a common side effect of the Losartan component, according to official product information.


Q: Is it normal to feel a bit light-headed when first starting Kenzar Plus?

A: The drug is associated with a risk of symptomatic hypotension (low blood pressure), particularly during the initiation of treatment in patients who have volume or salt depletion. This effect may result in feelings of dizziness or light-headedness.


Q: Does Kenzar Plus affect kidney function over time?

A: Drugs that inhibit the renin-angiotensin system (Losartan) and diuretics (HCTZ) can cause changes in renal function, which includes a risk of acute renal failure. Official information indicates that periodic monitoring of kidney function is recommended for susceptible patients.


Q: Can Kenzar Plus be stopped suddenly, or is a doctor's guidance needed?

A: This medication is intended for the chronic management of high blood pressure. While the label does not provide general instructions for discontinuation, the official label specifies circumstances where immediate discontinuation is required, such as the detection of pregnancy.


Q: How long does the effect of one dose of Kenzar Plus last?

A: The Losartan component's terminal half-life is described as approximately 6 to 9 hours. As the medication is typically prescribed for once-daily use, which is intended to provide continuous blood pressure coverage.


Q: Can Kenzar Plus affect my sleep?

A: Sleep disturbances, including insomnia (difficulty sleeping), have been reported in post-marketing experience with the medication. This effect is generally listed with an unknown frequency in regulatory documents.


Q: Are there any specific vitamins or supplements that should not be taken with Kenzar Plus?

A: Official information indicates that taking the medication with potassium supplements could increase the risk of high potassium levels (hyperkalemia). Additionally, combining it with supplements containing Calcium or Vitamin D may increase the risk of high blood calcium levels.


Q: What common foods or drinks are known to interact with Kenzar Plus?

A: The consumption of grapefruit or grapefruit juice may increase the absorption and effect of the Losartan component. Furthermore, eating foods that are very high in potassium may also increase the risk of hyperkalemia.


Q: Can Kenzar Plus be used for conditions other than high blood pressure, such as heart failure?

A: The fixed-dose combination is primarily indicated for the management of high blood pressure (hypertension). It is also approved to reduce the risk of stroke in patients with hypertension and a specific heart condition known as Left Ventricular Hypertrophy (LVH).


Q: Does Kenzar Plus cause swelling in the ankles or feet?

A: Edema, or swelling, has been reported as an adverse reaction in clinical studies or post-marketing experience with the medication. However, regulatory documents often classify this particular effect as having an uncommon or unknown frequency.


Q: How is Kenzar Plus different from an ACE inhibitor?

A: The Losartan component is an Angiotensin II Receptor Blocker (ARB), which works by blocking the receptor that Angiotensin II binds to. ACE inhibitors block the enzyme that creates Angiotensin II. In comparison to ACE inhibitors, the Losartan component is less likely to cause a cough because of this difference in how it works.


Q: Does Kenzar Plus affect potassium levels in the body?

A: Yes, the drug can affect potassium levels in two different ways. The diuretic component is commonly associated with potassium loss (hypokalemia), while the Losartan component can lead to an increase (hyperkalemia). Due to this potential dual effect, official information suggests periodic monitoring of potassium.


Q: Does Kenzar Plus contain a generic component?

A: Yes. The active ingredients contained in Kenzar Plus are Losartan Potassium and Hydrochlorothiazide. These are the established generic names of the two drugs in the combination.


Q: Does Kenzar Plus affect blood sugar or cholesterol levels?

A: Regulatory information indicates that the Hydrochlorothiazide component may cause increases in blood sugar levels (hyperglycemia). The combination is also known to affect other metabolic markers, such as uric acid levels.


Q: Are there specific symptoms that require immediate medical attention while taking Kenzar Plus?

A: Symptoms of a serious allergic reaction, such as swelling of the face, lips, throat, or tongue (Angioedema), are explicitly listed as serious adverse reactions. The label also lists specific eye problems as serious reactions to report.


Q: Is Kenzar Plus a long-term medicine, or is it used for short periods?

A: Official prescribing information indicates that this medication is intended for the chronic management of high blood pressure. It is typically used as a long-term therapy rather than for short periods.


Q: What does the 'Plus' mean in the name Kenzar Plus?

A: The use of 'Plus' in the name signifies that the product is a fixed-dose combination containing more than one active ingredient. Specifically, it represents the addition of the second blood pressure medicine, Hydrochlorothiazide, to the main drug, Losartan.


Q: What are the possible risks of taking Kenzar Plus with salt substitutes that contain potassium?

A: Official warnings indicate a significant risk of developing dangerously high blood potassium levels (hyperkalemia) when combined with potassium-containing salt substitutes. This is due to the potassium-retaining effect of the Losartan component.


Q: Why is monitoring kidney function important while taking Kenzar Plus?

A: Monitoring renal function is important because both drug classes—ARBs and diuretics—can cause changes in kidney function, including the risk of acute renal failure in certain patients. Official documents describe the need for periodic monitoring of renal function for susceptible patients.


Q: Is Kenzar Plus commonly prescribed for people with certain heart conditions?

A: The drug has an official indication to reduce the risk of stroke in patients with high blood pressure and a specific heart change called Left Ventricular Hypertrophy (LVH). This is in addition to its main use for general hypertension management.


Q: Does Kenzar Plus require periodic blood tests?

A: Due to the potential risk of fluid, electrolyte, and renal imbalances, official information indicates the need for periodic monitoring of kidney function and potassium levels for susceptible patients. This monitoring typically involves blood tests.


Q: Can Kenzar Plus make me feel dehydrated?

A: Because the Hydrochlorothiazide component is a diuretic, it increases urination, which may lead to dehydration and loss of electrolytes if fluid intake is inadequate. Low blood pressure resulting from this volume depletion can also occur.


Q: What are the signs of low blood pressure associated with Kenzar Plus?

A: Low blood pressure (hypotension) may cause you to feel dizzy or faint. Other reported signs of possible fluid or electrolyte imbalance include weakness, lethargy, excessive thirst, or restlessness.


Q: Can Kenzar Plus cause stomach upset or digestive issues?

A: Diarrhea is listed as a common side effect of the medication. Less common gastrointestinal issues, such as abdominal pain, nausea, and vomiting, have also been reported in clinical studies or post-marketing experience.


Q: Can Kenzar Plus cause a cough like some other blood pressure medicines?

A: Cough is listed as an adverse reaction in studies for the Losartan monotherapy. However, official information notes that the Losartan component is generally less likely to cause a cough compared to medications in the ACE inhibitor class.


Q: Are there any documented drug interactions with alcohol and Kenzar Plus?

A: Regulatory warnings describe that alcohol consumption, when combined with this medication, has the potential for additive effects in lowering blood pressure. This may increase the risk of symptoms like lightheadedness, dizziness, and fainting.


Q: Are there any common herbal remedies that interact with Kenzar Plus?

A: Regulatory documents do not provide a comprehensive list of interactions with herbal remedies. Due to a lack of testing data and potential effects on blood pressure or electrolytes, official documents recommend that patients inform their healthcare provider of all supplements and herbal remedies they are taking.

How should Kenzar Plus be stored and disposed of?

Storage and Disposal of Kenzar Plus

Kenzar Plus (losartan potassium and hydrochlorothiazide) tablets must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F) as defined in regulatory labeling.


  • Protection: The medication must be protected from excessive heat, moisture, and light. The container must be kept tightly closed and stored away from damp areas like a bathroom.
  • Child Safety: Kenzar Plus must be kept out of reach of children to prevent accidental ingestion.
  • Disposal: Unused or expired tablets must be disposed of according to local requirements for pharmaceutical waste. This typically involves using a drug take-back program or following official guidelines, such as those from the FDA, for safe household trash disposal if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kenzar Plus found in:

A-Z Index: